United States:
FDA Determines Levonorgestrel Drug Not Withdrawn For Reasons Of Safety Or Effectiveness
15 September 2014
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
Since the last Jones Day Update, FDA determined that JADELLE (levonorgestrel) Implant, 75mg was not
withdrawn for reasons of safety or effectiveness. This
determination will allow FDA to approve abbreviated new drug
applications for the drug, if all other legal and regulatory
requirements are met.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).